IMUNON to Participate in the H.C. Wainwright Global Investment Conference
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will...
Vaccine
Defence’s Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence"...
Walgreens Boots Alliance Announces Leadership Transition
Rosalind Brewer Steps Down as CEO and Member of the Board Ginger Graham, Current Lead Independent Director, Appointed Interim CEO...
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
PRINCETON, NJ / ACCESSWIRE / August 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical...
Moderna to Host Investor Event – R&D Day and Business Updates
CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor...
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit
STONY BROOK, NY / ACCESSWIRE / August 29, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
Vaxxinity to Present at Upcoming Investor Conferences in September
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
ENA Respiratory Expands Leadership Team and Extends U.S. Department of Defense Funding to Enable Phase II Program of INNA-051 in Community-Acquired Viral Respiratory Infections
-- New $3.8 million DOD contract extension will fund non-clinical safety studies to support a three-month seasonal prophylaxis Phase 2b...
Omega Therapeutics Announces Updates to its Board of Directors
Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed...
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel...
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
Saint-Herblain (France), August 28, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive...
CancerVAX CEO Ryan Davies Discussed Cancer Immunotherapy with UCLA Physician-Scientist
Dr. Steven Jonas commented about his journey to becoming both a practicing cancer doctor and active cancer researcherLEHI, Utah, Aug....
Cygnus Technologies Receives 2023 R&D 100 Award for MockV® RVLP Kit
LELAND, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Cygnus Technologies, part of Maravai LifeSciences (Maravai) (NASDAQ: MRVI), the leading product...
cbdMD, Inc. Suspends Monthly Dividend Payment on Its Series A Cumulative Convertible Preferred Stock
Charlotte, North Carolina--(Newsfile Corp. - August 22, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) today announced that its...
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria
60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of...
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering...
European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,...
Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update
Oslo, 22 August 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its...
Dr. Christian Brander and Dr. Mala Maini Join World-class Scientific Advisory Board of AstriVax
Christian Brander, Ph.D., is a leading expert on T cell responses to viral infections and brings an important blend of...